Skip to main content
Home
  • The Network
    • Membership
    • Who we are
    • Make the most of our services
    • Cambridge Cluster
    • Cambridge NeuroWorks
    • FAQ
  • Companies
    • Member directory
  • News
    • News listing
    • Blog
  • Events
    • All events
    • Cambridge Network events
    • Advertise your event
    • Boost your event
    • Sponsorship
  • Learning
    • Training courses
    • In-house courses
    • Coaching services
    • Graduate scheme
    • Consultancy services
    • Peer groups
    • Learning FAQ
  • Jobs
    • Jobs listing
    • Recruitment Packages
    • Advertise your vacancies
    • Connect with future talent
    • Boost your job
    • Tips for finding a job
More
    • Contact us
    • Join the network
    • My profile
    • Log in
    • The Network
      • Membership
      • Who we are
      • Make the most of our services
      • Cambridge Cluster
      • Cambridge NeuroWorks
      • FAQ
    • Companies
      • Member directory
    • News
      • News listing
      • Blog
    • Events
      • All events
      • Cambridge Network events
      • Advertise your event
      • Boost your event
      • Sponsorship
    • Learning
      • Training courses
      • In-house courses
      • Coaching services
      • Graduate scheme
      • Consultancy services
      • Peer groups
      • Learning FAQ
    • Jobs
      • Jobs listing
      • Recruitment Packages
      • Advertise your vacancies
      • Connect with future talent
      • Boost your job
      • Tips for finding a job

    Breadcrumb

    1. Home
    2. Healthcare and Life Science

    Healthcare and Life Science

    Respiratory Care Digital Innovation Opportunities
    12 August 2025

    Clinical insights: Respiratory care digital innovation opportunities

    Co-authored by Dr Bipin Patel, CEO, electronRx, Cambridge, UK and  Dr Hiromichi Yamaguchi, Yamaguchi Respiratory Clinic and Dermatology, Tokyo, Japan.  ...

    a low-cost, label-free cell sorter
    25 July 2025

    From complexity to clarity: analytics in cell and gene therapy

    Cell and gene therapies (CGTs) have redefined the treatment landscape, but their development and manufacturing remain uniquely challenging. They involve variable starting materials and complex, small-scale processes. As the field pushes for faster development, scalable manufacturing and...

    The Innovation Alley Exhibition at Cambridge Tech Week – a showcase of leading startups, scaleups, and cutting-edge tech.
    6 August 2025

    NPZ Technology and CCV to showcase cross-border innovation at Cambridge Tech Week 2025

    As Innovation Zone Sponsors at Cambridge Tech Week 2025, NPZ Technology Ltd and Cambridge Collaborative Ventures Ltd (CCV) will host an exhibition zone in Innovation Alley, featuring five cross-border innovation companies in digital health, VR, robotics, and AI. ...

    Antibodies.com
    4 August 2025

    Antibodies.com expands UK headquarters with new 5x larger facilities in Cambridge to accommodate rapid growth

    Cambridge, UK, 04 August 2025: Antibodies.com, a trusted provider of high-quality biological reagents for life science researchers, today announced the expansion of its UK headquarters with a move to Cambridge Technopark to accommodate the Company’s rapid growth. The new 5000 sq. ...

    Women and men surgeons in operating room
    15 August 2025

    Team Consulting and inclusive surgical devices at Royal College of Surgeons of England event

    Team Consulting are attending the Women at the Cutting Edge event hosted by the Royal College of Surgeons of England, in partnership with the RCS England I-Hub and Women in Surgery (WinS) group, on Friday 17th October 2025 at the Birmingham Repertory Theatre. Team's Senior FEI Strategy...

    Patient undergoing imaging for cancer treatment
    30 June 2025

    Radiotherapy and surgical ablation technologies for cancer treatment

    Radiotherapy, or radiation ablation, has evolved significantly since its inception. Ongoing technological advancements have the potential to position radiotherapy as a first-line “surgical” treatment for solid tumours by enhancing its precision and efficacy. Further advancements in real...

    Image of a woman with an engineering model on a computer
    11 June 2025

    How surrogate models enhance medical device optimisation

    Design optimisation is a fundamental step in developing innovative and efficient medical devices. Before committing to manufacturing prototypes, simulations and models are developed to indicate the expected performance of the medical device design. They offer great precision however,...

    Preventing patient hospitalisation
    30 July 2025

    Preventing patient hospitalisation through better stratification and timely intervention

    In the realm of healthcare, patient hospitalisation can often be avoided through timely intervention and appropriate medication management. One powerful strategy to achieve this is patient stratification—classifying patients into different groups based on their vulnerability to hos...

    Dr. Erin Duffy, Chief of Research and Development, CARB-X	Dr. Jennifer Schneider, Chief Executive Officer, Centauri Therapeutics
    29 July 2025

    Centauri Therapeutics receives an additional $5.1M from CARB-X to progress ABX-01 lead compound to first in human clinical trials

    CARB-X provides an additional $5.1M to complete the non-clinical safety and efficacy studies with ABX-01 lead candidateCentauri plans the progression of lead candidate, an immunotherapy based broad-spectrum antimicrobial, to a first in human clinical study in early 2026CARB-X’s addition...

    Dr Catherine Beech, CEO, Exonate	Imaging from Phase IIa study demonstrates significant reduction in vascular leakage, a critical marker for NDPR
    29 July 2025

    Exonate plans ‘CLEAR-DE’ Phase IIb clinical trial of lead candidate EXN407 for diabetic eye disease

    EXN407 is the first topical SRPK1 inhibitor to demonstrate safety and efficacy as a monotherapy for non-proliferative diabetic retinopathy (NPDR) and diabetic macular oedemaPhase IIb trial to investigate efficacy in NPDR patients to commence in Q1 2026Cambridge, UK, 29 July 2025: E...

    Pagination

    • First page «
    • Previous page ‹‹
    • …
    • Page 83
    • Page 84
    • Current page 85
    • Page 86
    • Page 87
    • …
    • Next page ››
    • Last page »
    Receive our newsletter

    Footer menu

    • Terms & Conditions
    • Disclaimer
    • Privacy
    • Cookies
    • FAQ

    Cambridge Network Limited is a company registered in England under company No. 3400152

    The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

    Email: [email protected], Tel: 01223 746801

    © 2026 Cambridge Network. All Rights Reserved.

    Website by KISS